San Diego, Calif., October 19, 2017 – Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, announced today that data from its Phase 1 clinical study of octreotide acetate for intranasal administration (DP1038), will be presented at the annual North American Neuroendocrine Tumor Society (NANETS) Symposium, October 19-21, in Philadelphia, Pennsylvania.
Dr. Matteo Levisetti, Chief Medical Officer for Dauntless, will present data from the recently-completed Phase 1 clinical study that assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of DP1038, an intranasal formulation of octreotide acetate, in healthy volunteers. DP1038 demonstrated an excellent safety and pharmacokinetic profile as well as on-target pharmacological effects that support the continued development of the product.
DP1038 leverages patented technology for enhanced intranasal absorption developed by Aegis Therapeutics, LLC, and is being developed as a non-injectable alternative for the treatment of patients with acromegaly and the symptomatic treatment of patients with carcinoid tumors. Specifically, octreotide has been shown to be efficacious in reducing the debilitating diarrhea and flushing episodes associated with metastatic carcinoid tumors. The somatostatin analog market currently exceeds $2 billion annually with all commercially available formulations requiring subcutaneous or intramuscular injections.
Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. Dauntless 1, its first asset company, was formed to develop DP1038, a therapeutic agent for the treatment of acromegaly and neuroendocrine tumors. Launched in 2015, Dauntless Pharmaceuticals has raised committed capital of $32 million from Sofinnova and Canaan Partners.